ARTICLE | Product Development
GSK study highlights disease prevalence as key to trial diversity
Retrospective study of 495 GSK trials in the U.S. shows the need to look beyond census data when constructing diversity plans
February 7, 2023 12:57 AM UTC
GSK’s look back at 495 trials conducted over 17 years spotlights how epidemiological data, not census demographic data, is the standard to meet for clinical trial diversity.
The study’s conclusions echo calls from patient advocates in underrepresented groups...